Papers: 24 Sep 2012 - 1 Oct 2012
Cross-Immunoreactivity between Bacterial Aquaporin-Z and Human Aquaporin-4: Potential Relevance to Neuromyelitis Optica.
Glatiramer acetate ameliorates inflammatory bowel disease in mice through the induction of Qa-1-restricted CD8⁺ regulatory cells.
Visual evoked potentials in early diagnosis of demyelinating diseases - a case report of Devic's disease.
Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica.
Synthetic lethality for linking the mycophenolate mofetil mode of action with molecular disease and drug profiles.
Improved ability to work after one year of natalizumab treatment in multiple sclerosis. Analysis of disease-specific and work-related factors that influence the effect of treatment.
Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis optica.
[The neurodegenerative process in multiple sclerosis and the possible neuroprotective effect of treatment with Β-interferon 1a (avonex).]
Expanded functional coupling of subcortical nuclei with the motor resting-state network in multiple sclerosis.
[Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].
Harnessing monocyte-derived macrophages to control central nervous system pathologies: No longer 'if' but 'how'
Acute transverse myelitis following Japanese encephalitis viral infection: an uncommon complication of a common disease.
Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
Self-efficacy and health status improve after a wellness program in persons with multiple sclerosis.
Disease mechanisms in MS: A role for sodium channels in regulation of macrophage-mediated pathology in multiple sclerosis lesions.
Blood-Brain Barrier Alterations in the Cerebral Cortex in Experimental Autoimmune Encephalomyelitis.
[Therapeutic effect of encapsulated into the nanocontainers MBP immunodominant peptides on EAE development in DA rats].
Baseline brain activity changes in patients with clinically isolated syndrome revealed by resting-state functional MRI.
Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study.
Role of Venoplasty for Treatment of Multiple Sclerosis: Value of Open-label Studies and Surrogate Treatment Outcomes.
A Potent and Selective S1P(1) Antagonist with Efficacy in Experimental Autoimmune Encephalomyelitis.
Transglutaminase 2 exacerbates experimental autoimmune encephalomyelitis through positive regulation of encephalitogenic T cell differentiation and inflammation.
MHC2TA mRNA levels and human herpesvirus 6 in multiple sclerosis patients treated with interferon beta along two-year follow-up.
Geomagnetic disturbances may be environmental risk factor for multiple sclerosis: an ecological study of 111 locations in 24 countries.
Regulatory role of vitamin D in T-cell reactivity against myelin peptides in relapsing-remitting multiple sclerosis patients.
Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study.